Select Your Region
Americas
Europe
Africa
Global
A Study of Tocilizumab in Chinese Participants With Systemic Juvenile Idiopathic Arthritis (sJIA)
- Autoimmune Disorder
- Juvenile Idiopathic Arthritis
Please note that the recruitment status of the study at your site may differ from the overall study status because some study sites may recruit earlier than others.
Study Status:
Completed
This study runs in
Country
- China
Study Identifier:
NCT03301883 YA39368
Study Summary
This Phase IV, multicenter, single-arm, open-label study will evaluate the efficacy and safety of tocilizumab in Chinese participants with sJIA with persistent activity and an inadequate response to non-steroidal anti-inflammatory drugs (NSAIDs) and steroid therapy.
Hoffmann-La Roche
Sponsor
Phase 4
Phase
NCT03301883, YA39368
Study Identifier
Tocilizumab, NSAIDs, CSs, MTX
Treatments
Juvenile Idiopathic Arthritis
Condition
Official Title
A Phase IV, Multicenter, Single-Arm, Open-Label Study to Assess the Efficacy and Safety of Tocilizumab in Chinese Patients With Systemic Juvenile Idiopathic Arthritis
Eligibility Criteria
All
Gender
≥ 2 Years & ≤ 17 Years
Age
No
Healthy Volunteers
Inclusion Criteria
- Participants meeting International League of Associations for Rheumatology (ILAR) classification for sJIA
- Greater than (>) 6 months of documented persistent sJIA activity prior to screening
- Active disease
- hsCRP >4.3 milligrams per liter (mg/L) or 0.43 milligrams per deciliter (mg/dL)
- Participant who has recovered from any symptomatic serositis for at least 30 days prior to the screening visit, and requires a dose of CSs at baseline of </=30 mg/day or </=0.5 mg/kg/day, whichever is less
- Participants meeting one of the following: Participant who is not receiving MTX or discontinued MTX >/=4 weeks prior to baseline visit; participant who has been taking MTX >/=12 weeks immediately prior to the baseline visit and on a stable dose of </=20 mg/m^2 for >/=8 weeks prior to the baseline visit, together with either folic acid or folinic acid according to local standard of care
- Participant who was never treated with biologics or, if was previously treated with biologics, discontinued etanercept (or Yisaipu, Qiangke, or Anbainuo) >/=2 weeks, infliximab or adalimumab >/=8 weeks, anakinra >/=1 week, or abatacept >/=12 weeks prior to the baseline visit
- Participant who is not currently receiving oral CSs, or is taking oral CSs at a stable dose for >/=2 weeks prior to the baseline visit at </=30 mg/day or </=0.5 mg/kg/day, whichever is less
- Participant who is not taking NSAIDs, or taking </=1 type of NSAID at a stable dose for >/=2 weeks prior to the baseline visit and is less than or equal to the maximum recommended daily dose
Exclusion Criteria
- Wheelchair bound or bedridden participant
- Any other autoimmune, rheumatic disease, or overlap syndrome other than sJIA
- Participant who is not fully recovered from recent surgery or <6 weeks since surgery at the time of screening visit; or planned surgery during the initial 12 weeks of the study
- Lack of peripheral venous access
- Any significant concurrent medical or surgical condition that would jeopardize the participant's safety or ability to complete the trial
- Evidence of serious uncontrolled concomitant diseases
- Asthma for which the participant has required the use of oral or parenteral CSs for >/=2 weeks within 6 months prior to the baseline visit
- Known human immunodeficiency (HIV) infection or other acquired forms of immune compromise or congenital conditions characterized by a compromised immune system
- Any active acute, subacute, chronic, or recurrent bacterial, mycobacterial, viral, or systemic fungal infection or opportunistic infection
- Any major episode of infection requiring hospitalization or treatment during screening, treatment with IV antibiotics completing within 4 weeks of the screening visit, or oral antibiotics completing within 2 weeks of the screening visit
- History of atypical tuberculosis (TB)
- Active TB requiring treatment within 2 years prior to screening visit
- Positive purified protein derivative (PPD) or T-spot test (interferon-gamma [IFN-γ]-based test) at screen
- Positive for latent TB
- History of reactivation or new onset of a systemic infection such as herpes zoster or Epstein-Barr virus (EBV) within 2 months of the screening visit
- Hepatitis B surface antigen (Ag)- or hepatitis C antibody (Ab)-positive
- History of macrophage activation syndrome (MAS) within 3 months prior to the screening visit
- Evidence of active malignant disease or diagnosed malignancies
- Uncontrolled diabetes mellitus
- Previous treatment with tocilizumab
- Intra-articular, intramuscular, IV, or long-acting CSs administration within 28 days prior to the baseline visit
- Treatment with non-biologic disease-modifying antirheumatic drugs (DMARDs; other than MTX) within 6 weeks prior to the baseline visit
- Treatment with leflunomide that was not followed by standardized cholestyramine washout and documented to be below the limit of detection prior to the baseline visit
- Treatment with cyclophosphamide, etoposide (VP16) and statins within 90 days prior to the baseline visit
- Treatment with growth hormone and androgens within 4 weeks prior to the baseline visit
- Administration of IV immunoglobulin within 28 days prior to the baseline visit
- Treatment with any cell-depleting therapies
- Stem cell transplant at any time
- Participant who has received live or attenuated vaccines within 4 weeks prior to the baseline visit, or intending to receive while on study drug or 3 months following the last dose of study drug
For the latest version of this information please go to www.forpatients.roche.com